

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### A. FURTHER INFORMATION ABOUT OUR COMPANY

#### 1. Incorporation

Our Company was incorporated in the PRC on February 12, 1999, and was converted into a joint stock limited company on October 25, 2001. Our Company completed the listing of our A Shares on the Shenzhen Stock Exchange (stock code: 002020) on July 15, 2004.

As of the date of this document, our Company’s registered address and headquarters are located at No. 800 Xinchang East Road, Yulin Subdistrict, Xinchang, Zhejiang Province, PRC. Our Company’s corporate structure and Articles of Association are governed by PRC laws and regulations.

The relevant PRC laws and regulations and a summary of the Articles of Association are set out in “Appendix V — Summary of Articles of Association” to this document, respectively.

Our principal place of business in Hong Kong is at [46/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong]. Our Company is [registered] with the Registrar of Companies in Hong Kong as a non-Hong Kong company under Part 16 of the Companies Ordinance on [●]. Ms. CHAN Ching Nga has been appointed as the authorized representative of our Company for the acceptance of service of process and notices on behalf of our Company in Hong Kong. Her address for acceptance of service of process is the same as our principal place of business in Hong Kong.

#### 2. Changes in Share Capital of Our Company

There has been no alteration in the [REDACTED] of our Company within two years immediately preceding the date of this document.

#### 3. Changes in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our principal subsidiaries are set out in Note 17 to the Accountant’s Report as set out in Appendix I to this document.

*Zhejiang Jingjianyuan Medical Technology Co., Ltd. (浙江京健元醫療科技有限公司)*

On March 4, 2024, the authorized [REDACTED] of Zhejiang Jingjianyuan Medical Technology Co., Ltd. increased from RMB10,000,000 to RMB20,000,000, and was increased from RMB20,000,000 to RMB20,266,666 on December 24, 2024.

*HK Jingxin Global Limited (香港京新有限公司)*

On November 4, 2025, HK Jingxin Global Limited was incorporated with an authorized [REDACTED] of HK\$1,000,000 divided into 1,000,000 ordinary shares of HK\$1.00 each.

Save as disclosed above, there has been no alteration in the [REDACTED] of any of the operating entities of the Company within the two years immediately preceding the date of this document.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 4. Resolutions of Our Shareholders in Relation to the [REDACTED]

At the general meeting of our Company held on January 28, 2026, the following resolutions were passed by the Shareholders:

- (a) the [REDACTED] of H shares with a nominal value of RMB1.00 each by our Company and such H Shares be [REDACTED] on the [REDACTED];
- (b) the number of H Shares to be [REDACTED] pursuant to the [REDACTED] before the exercise of the [REDACTED] shall not exceed 15% of the enlarged [REDACTED] of our Company upon the completion of the [REDACTED], and the [REDACTED] shall not exceed 15% of the above number of H Shares to be [REDACTED];
- (c) subject to the completion of the [REDACTED], the Articles of Association to become effective on the [REDACTED] shall be conditionally adopted, and the Board and its authorized person have been authorized to amend the Articles of Association in accordance with any comments from the relevant regulatory authorities; and
- (d) to authorize the Board and its authorized person to handle the matters relating to, among others, the [REDACTED], the [REDACTED] and the [REDACTED] of the H Shares.

## B. FURTHER INFORMATION ABOUT OUR BUSINESS

### 1. Summary of Material Contracts

The following contract (not being contracts entered into in the ordinary course of business) has been entered into by us within the two years preceding the date of this document and are or may be material:

- (a) [REDACTED].

### 2. Our Material Intellectual Property Rights

#### (a) Trademarks

##### (i) Registered trademarks

As of the Latest Practicable Date, our Company had registered the following trademarks which we consider to be or may be material to our business:



吉易克

京可新

京新

唯他停

京常乐

京诺宁



京诺

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

*(ii) Trademarks under application*

As of the Latest Practicable Date, we had applied for the registration of the following trademarks which we consider to be or may be material to our business:

<u>No.</u>	<u>Trademark</u>	<u>Place of Application</u>	<u>Application No.</u>	<u>Applicant</u>	<u>Class</u>	<u>Application Date</u>
1.		Hong Kong	307101675	The Company	5	November 21, 2025
2.		Hong Kong	307126344	The Company	16	December 12, 2025

*(b) Patents*

As of the Latest Practicable Date, we were the registered owner of and had the right to use the following patents which we consider to be or may be material to our business:

*(i) Registered patents*

<u>No.</u>	<u>Patent</u>	<u>Patentee</u>	<u>Place of Registration</u>	<u>Patent Number</u>	<u>Application Date</u>
1.	Treatment of sleep disorders (睡眠障礙的治療)	the Company	PCT	CN101827597B, US10370378B2, DE602008055451T2, JP5545873B2	August 19, 2008
2.	Benzodiazepine compound solid forms, and preparation methods therefor and applications thereof (一種苯並二氮雜草化合物的固態形式及其製備方法和應用)	the Company	PRC	CN109134471B	June 27, 2017

*(ii) Pending Patents*

As of the Latest Practicable Date, we had not applied for the registration of the patents which we consider to be or may be material to our business.

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

*(c) Copyrights*

*Registered copyrights*

As of the Latest Practicable Date, we were the registered owner of and had the right to use the following copyrights which we consider to be or may be material to our business:

<u>No.</u>	<u>Name</u>	<u>Copyright Owner</u>	<u>Place of Registration</u>	<u>Registration No.</u>	<u>Date of Publication</u>
1.	Software for periodic QA and calibration based on front-mounted sensors (基於前置sensor的定期QA和校準軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2025SR1477992	August 7, 2025
2.	Digital operating room control system (數字化手術室控制系統)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2024SR0664773	May 16, 2024
3.	Medical consultation multi-window multi-host real-time touch interaction system (醫用會診多視窗多主機實時觸控交互系統)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2023SR0226239	February 10, 2023
4.	Medical multi-window consultation control and display system (醫用多視窗會診控制顯示系統)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2022SR1474307	November 4, 2022
5.	Digital operating room centralized management and monitoring system (數字化手術室集中管理及監控系統)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2022SR1300437	August 26, 2022
6.	Jufeng medical display automatic color correction system software (巨烽醫用顯示自動色彩校正系統軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2021SR0058344	January 12, 2021
7.	Jufeng medical display mouse positioning control software (巨烽醫用顯示鼠標定位控制軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2020SR1739250	December 4, 2020
8.	Jufeng monitor GAMMA curve correction software (巨烽顯示器GAMMA曲線校正軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2020SR1741676	December 4, 2020

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

<u>No.</u>	<u>Name</u>	<u>Copyright Owner</u>	<u>Place of Registration</u>	<u>Registration No.</u>	<u>Date of Publication</u>
9.	Jufeng medical multi-display mouse adaptive software (巨烽醫用多顯示鼠標自適應軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2020SR1739260	December 4, 2020
10.	Jufeng control panel test simulation software (巨烽控制面板測試仿真軟件)	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)	PRC	2014SR209828	December 25, 2014

**(d) Domain Names**

As of the Latest Practicable Date, we have registered the following domain name that we consider to be or may be material to our business:

<u>No.</u>	<u>Domain Name</u>	<u>Registrant</u>
1.	jingxinpharm.com; jingxin-pharm.com; china-jingxin.com	the Company
2.	183.131.95.33	the Company
3.	beacon-display.cn	Shenzhen Beacon Display Technology Co., Ltd. (深圳市巨烽顯示科技有限公司)
4.	shaxiliangcha.cn	Guangdong Shaxi Pharmaceutical Co., Ltd. (廣東沙溪製藥有限公司)
5.	shaxizhiyao.com; gdsxzy.com; shaxipharm.com	Guangdong Shaxi Pharmaceutical Co., Ltd. (廣東沙溪製藥有限公司)

Save as disclosed above, as of the Latest Practicable Date, there were no other trade or service marks, patents, intellectual or industrial property rights which were material in relation to our business.

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

**C. FURTHER INFORMATION ABOUT DIRECTORS, CHIEF EXECUTIVE AND SUBSTANTIAL SHAREHOLDERS OF OUR COMPANY**

**1. Particulars of Directors' Service Contracts and Letters of Appointment**

Our Company has entered into a service agreement or appointment letter with each of the Directors. The principal particulars of these service agreements and appointment letters are: (a) each of the agreement or letter is for a term of three years following the commencement date of his/her term of office; and (b) each of the agreement or letter is subject to termination in accordance with their respective terms. The service agreements and appointment letters may be renewed in accordance with our Articles of Association and the applicable laws, rules and regulations from time to time.

Save as disclosed above, our Directors has not entered into or propose to enter into any service contracts with any member of our Group (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

**2. Remuneration of Directors**

The aggregate remuneration (including fees, salaries, allowances, benefits in kind, discretionary bonuses, retirement scheme contributions) paid to our Directors for the two years ended December 31, 2023, 2024 and the ten months ended October 31, 2025, were approximately RMB7.0 million, RMB7.1 million and RMB6.0 million, respectively.

It is estimated that remuneration equivalent to approximately RMB7.1 million in aggregate will be paid to the Directors by our Company for the year ending December 31, 2025, based on the arrangements in force as of the date of this document.

No remuneration was paid by our Company to the Directors or the five highest paid individuals as inducement to join or upon joining our Company or as a compensation for loss of office during the Track Record Period. Furthermore, none of the Directors had waived or agreed to waive any remuneration during the Track Record Period. Save as disclosed above, during the Track Record Period, no other amounts shall be paid or payable by us or any of our subsidiaries to our Directors or the five highest paid individuals.

Save as disclosed above, no other payments have been made or are payable in respect of the two years ended December 31, 2023 and 2024 and the ten months ended October 31, 2025, by any member of our Group to any of our Directors.

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

**3. Disclosure of interests**

*Disclosure of interests of Directors and chief executive of our Company*

To the best knowledge of our Directors, saved as disclosed below, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised), the interest or short position of our Directors or chief executives of our Company in the Shares, underlying Shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interest or short positions which they were taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, to be notified to our Company and the Hong Kong Stock Exchange, once the Shares are [REDACTED] will be as follows:

(i) *Interests in Shares of our Company*

<u>Name of Director</u>	<u>Title</u>	<u>Nature of interest</u>	<u>Number of Shares held Immediately following Completion of the [REDACTED]<sup>(1)</sup></u>	<u>Approximate percentage of interest in our Company immediately following Completion of the [REDACTED]</u>
Mr. LYU Gang	Chairperson of the Board, executive Director, general manager	Beneficial owner	178,796,755 A Shares (L)	[REDACTED]
		Interest in controlled corporations <sup>(2)</sup>	134,966,393 A Shares (L)	[REDACTED]
		Interest of spouse <sup>(3)</sup>	134,966,393 A Shares (L)	[REDACTED]

*Notes:*

- (1) The letter “L” denotes the person’s long position in the Shares.
- (2) As of the Latest Practicable Date, Jingxin Holding was owned as to 51% by Mr. LYU Gang and 49% by Jinzhi Investment, respectively. As of Latest Practicable Date, Jinzhi Investment was owned as to 60% by Mr. LYU Gang and 40% by Ms. ZHANG Liling, respectively. Therefore, Mr. LYU Gang is deemed to be interested in 134,966,393 A Shares held by Jingxin Holding.
- (3) Mr. LYU Gang is the husband of Ms. ZHANG Liling. Therefore, Mr. LYU Gang is deemed to be interested in the interest of Ms. ZHANG Liling.

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

*Disclosure of interests of substantial shareholders*

(i) *Interests in Shares of our Company*

Save as disclosed in “Substantial Shareholders,” our Directors were not aware of any persons who would, immediately following the completion of the [REDACTED] (assuming (i) the [REDACTED] is not exercised and (ii) no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [REDACTED]), having interests or short positions in our Shares or underlying Shares which would be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at Shareholders’ general meetings of our Company.

(ii) *Interests in Our Subsidiaries*

As of the Latest Practicable Date, to the best knowledge of our Directors, the following persons (other than members of our Group, the Directors or chief executive of our Company) were interested in 10% or more of the voting rights at general meetings of our Subsidiaries:

<u>Name of Subsidiary</u>	<u>Name of substantial shareholder</u>	<b>Approximate % of voting rights held by substantial shareholder</b>
Hangzhou Jingrui Pharmaceutical Technology Co., Ltd. (杭州京瑞醫藥科技有限公司)	Ningbo Meishan Bonded Port Area Mingze Equity Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區鳴澤股權投資管理合夥企業(有限合夥))	45.00%
Yunnan Jingxin Biotechnology Co., Ltd. (雲南京新生物科技有限公司)	Mr. XIAO Hua (肖華)	10.00%
Shenyang TORCH-BIGTIDE DIGITAL Technology Co., Ltd. (瀋陽火炬北泰數碼科技有限責任公司)	Shenyang Huoju Co., Ltd. (瀋陽火炬股份有限公司) <sup>(1)</sup>	15.30%
	Shenyang Technology Venture Capital Co., Ltd. (瀋陽科技風險投資有限公司) <sup>(1)</sup>	9.02%

*Note:*

(1) To the best of the Directors’ knowledge, Shenyang Huoju Co., Ltd. (瀋陽火炬股份有限公司) and Shenyang Technology Venture Capital Co., Ltd. (瀋陽科技風險投資有限公司) are acting in concert.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 4. Agency Fees or Commissions Received

Save as disclosed in the section headed “[REDACTED]” in this document, no commissions, discounts, brokerages or other special terms were granted within the two years preceding the date of this document in connection with the [REDACTED] or sale of any capital or security of any member of our Group.

### 5. Disclaimers

- (a) save as disclosed in the sections headed “Substantial Shareholders” and “ — C. Further Information about our Directors, Chief Executive and Substantial Shareholders — 3. Disclosure of interests — Disclosure of interests of Directors and chief executive of our Company”, none of our Directors or the chief executive of our Company has any interest or short position in the Shares, underlying Shares or debentures of our Company or any of its associated corporation (within the meaning of the SFO) which will have to be notified to our Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to our Company and the Hong Kong Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers once the H Shares are [REDACTED];
- (b) none of our Directors or any of the experts referred to under paragraph headed “D. Other Information — 11. Qualification of Experts” in this Appendix has any direct or indirect interest in the promotion of our Company, or in any assets which have within the two years immediately preceding the date of this document been acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (c) save as disclosed in the sections headed “Directors and Senior Management — Compensation of Directors and Senior Management” and “ — C. Further Information about our Directors, Chief Executive and Substantial Shareholders — 1. Particulars of Directors’ Service Contracts and Letters of Appointment”, none of our Directors has any existing or proposed service contracts with any member of our Group (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation));
- (d) save as disclosed in the sections headed “Substantial Shareholders” and “ — C. Further Information about our Directors, Chief Executive and Substantial Shareholders — 3. Disclosure of interests — Disclosure of interests of Directors and chief executive of our Company”, so far as is known to our Directors or the chief executive of our Company, no person (not being a Director or chief executive of our Company) will, immediately following the completion of the [REDACTED], have an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of SFO or be interested, directly or indirectly, in 10% or more of the nominal value of any class of [REDACTED] carrying rights to vote in all circumstances at general meetings of any member of our Group; and

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

- (e) save as disclosed in the sections headed “Business — Customers” and “Business — Suppliers”, none of our Directors or their respective close associates (as defined under the Listing Rules) or our Shareholders who are interested in more than 5% of the issued [REDACTED] of our Company has any interest in the five largest customers or the five largest suppliers of our Group.

### 6. A Shares Participation Scheme

#### *2019 A Shares Participation Scheme (Phase I)*

The following is a summary of the principal terms of the 2019 A Shares Participation Scheme (Phase I). The terms of the 2019 A Shares Participation Scheme (Phase I) do not involve any grant of participation Shares by our Company after the [REDACTED] and are not subject to the provisions of Chapter 17 of the Listing Rules. The terms of the 2019 A Shares Participation Scheme (Phase I) are summarized below.

#### *(a) Purpose*

The purposes of the 2019 A Shares Participation Scheme (Phase I) are to align the interests of our Company, our shareholders and key employees, to attract and retain core talent, to enhance the initiative of our employees, and to support our Company’s long-term strategy and sustainable development.

#### *(b) Type and Source of Shares*

The A Share Incentives are granted in the form of participation Shares (“**Participation Shares**”). The Shares underlying the scheme shall be Participation Shares issued by our Company, which were repurchased from the secondary market or A shares held in the repurchase account of the Company.

#### *(c) Administration*

The 2019 A Shares Participation Scheme (Phase I) is subject to the approval of the Company’s general meeting and will be administered by a management committee (the “**Management Committee**”) authorized by the participants.

#### *(d) Participants*

Persons eligible to participate in the 2019 A Shares Participation Scheme (Phase I) are the Directors, senior management, core technical and business personnel and other core backbone employees of the Company, and other employees as determined by the Board.

#### *(e) Maximum Entitlement of a Participant*

The number of Shares granted to any individual participants under the 2019 A Shares Participation Scheme (Phase I) shall not exceed 1% of our Company’s total share capital. The total number of Participation Shares involved with 2019 A Shares Participation Scheme (Phase I) shall not exceed 10% of the total outstanding share capital of the Company.

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

*(f) Term*

This term of the 2019 A Shares Participation Scheme (Phase I) commences from the date the Company announces the grant of the Participation Shares and will remain effect for an indefinite period until the earliest of (i) a change of control of the Company; (ii) an early termination upon approval from the participants and the Board; or (iii) the reserve of the 2019 A Shares Participation Scheme (Phase I) fails to meet the funding requirements for distribution. If the reserve of the 2019 A Shares Participation Scheme (Phase I) fails to meet the funding requirements for distribution, the 2019 A Shares Participation Scheme (Phase I) shall automatically terminate. The Management Committee shall then proceed to liquidate the assets of the 2019 A Shares Participation Scheme (Phase I). After paying relevant taxes and fees, the remaining assets shall be distributed to the participants in proportion to their respective shareholdings.

*(g) Lock-up Arrangements*

The lock-up arrangements under the 2019 A Shares Participation Scheme (Phase I) are determined according to the Articles of Association and applicable PRC laws and regulations.

Participation Shares granted under the 2019 A Shares Participation Scheme (Phase I) are generally subject to a lock-up period of 36 months with a statutory lock-up of 12 months from the date of grant. The 2019 A Shares Participation Scheme (Phase I) shall comply with the prohibited period stipulated by the CSRC and the Shenzhen Stock Exchange. During the lock-up period, unless otherwise provided by laws, administrative regulations, or approved by the Management Committee, the Participation Shares held by the participants under the 2019 A Shares Participation Scheme (Phase I) shall not be transferred, pledged, or otherwise disposed of in a similar manner.

*(h) Distributions*

The 2019 A Shares Participation Scheme (Phase I) provides staged distributions of stock proceeds from sale of Participation Shares:

- (i) In the first year after the expiration of the [REDACTED] period, participants shall receive the first stock proceeds distribution from the Management Committee, which includes each participant's initial personal contribution and the corresponding portion of the Company's reward fund under the 2019 A Shares Participation Scheme (Phase I);
- (ii) In the second year after the expiration of the [REDACTED] period, the Management Committee shall distribute stock proceeds, corresponding to 20% of the initial scale of the 2019 A Shares Participation Scheme (Phase I) every two years, for a total of five rounds of distributions;
- (iii) After the above six rounds of distributions, any remaining stock proceeds of the participants under the 2019 A Shares Participation Scheme (Phase I) shall be available for withdrawal in a lump sum upon their retirement.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *2019 A Shares Participation Scheme (Phase II)*

The following is a summary of the principal terms of the 2019 A Shares Participation Scheme (Phase II). The terms of the 2019 A Shares Participation Scheme (Phase II) do not involve any grant of A Shares by our Company after the [REDACTED] and are not subject to the provisions of Chapter 17 of the Listing Rules. The terms of the 2019 A Shares Participation Scheme (Phase II) are summarized below.

#### *(a) Purpose*

The purposes of the 2019 A Shares Participation Scheme (Phase II) are to align the interests of our Company, our shareholders and key employees, to attract and retain core talent, to enhance the initiative of our employees, and to support our Company’s long-term strategy and sustainable development.

#### *(b) Type and Source of Shares*

The A Share Incentives are granted in the form of participation Shares (“**Participation Shares**”). The Shares underlying the scheme shall be Participation Shares issued by our Company, which were repurchased from the secondary market or A shares held in the repurchase account of the Company.

#### *(c) Administration*

The 2019 A Shares Participation Scheme (Phase II) is subject to the approval of the Company’s general meeting and will be administered by a management committee (the “**Management Committee**”) authorized by the participants.

#### *(d) Participants*

Persons eligible to participate in the 2019 A Shares Participation Scheme (Phase II) are the Directors, senior management, core technical, middle-level management personnel and other core backbone employees of the Company.

#### *(e) Maximum Entitlement of a Participant*

The number of Shares granted to any individual participants under the 2019 A Shares Participation Scheme (Phase II) shall not exceed 1% of our Company’s total [REDACTED]. The total number of Participation Shares involved with 2019 A Shares Participation Scheme (Phase II) shall not exceed 10% of the total outstanding [REDACTED] of the Company.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *(f) Term*

This term of the 2019 A Shares Participation Scheme (Phase II) commences from the date the Company announces the grant of the Participation Shares and will remain effect for an indefinite period until the earliest of (i) a change of control of the Company; (ii) an early termination upon approval from the participants and the Board; or (iii) the reserve of the 2019 A Shares Participation Scheme (Phase II) fails to meet the funding requirements for distribution. If the reserve of the 2019 A Shares Participation Scheme (Phase II) fails to meet the funding requirements for distribution, the 2019 A Shares Participation Scheme (Phase II) shall automatically terminate. The Management Committee shall then proceed to liquidate the assets of the 2019 A Shares Participation Scheme (Phase II). After paying relevant taxes and fees, the remaining assets shall be distributed to the participants in proportion to their respective shareholdings.

### *(g) Lock-up Arrangements*

The lock-up arrangements under the 2019 A Shares Participation Scheme (Phase II) are determined according to the Articles of Association and applicable PRC laws and regulations.

Participation Shares granted under the 2019 A Shares Participation Scheme (Phase II) are generally subject to a lock-up period of 48 months with a statutory lock-up of 12 months from the date of grant. The 2019 A Shares Participation Scheme (Phase II) shall comply with the prohibited period stipulated by the CSRC and the Shenzhen Stock Exchange. During the lock-up period, unless otherwise provided by laws, administrative regulations, or approved by the Management Committee, the Participation Shares held by the participants under the 2019 A Shares Participation Scheme (Phase II) shall not be transferred, pledged, or otherwise disposed of in a similar manner.

### *(h) Distributions*

The 2019 A Shares Participation Scheme (Phase II) provides staged distributions of stock proceeds from sale of Participation Shares:

- (i) In the fifth year from the date on which the funds of the 2019 A Shares Participation Scheme (Phase II) are received, participants shall receive the first stock proceeds distribution from the Management Committee, with the amount distributed corresponds to 1.5 times of each participant's initial personal contribution (the "**First Distribution**");
- (ii) In the third year after the First Distribution, the Management Committee shall distribute stock proceeds every three years, with each distribution amount corresponding to 50% of each participant's initial personal contribution;
- (iii) After the above distributions, any remaining stock proceeds of the participants under the 2019 A Shares Participation Scheme (Phase II) shall be available for withdrawal in a lump sum upon their retirement.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *2020 A Shares Participation Scheme (Phase III)*

The following is a summary of the principal terms of the 2020 A Shares Participation Scheme (Phase III). The terms of the 2020 A Shares Participation Scheme (Phase III) do not involve any grant of A Shares by our Company after the [REDACTED] and are not subject to the provisions of Chapter 17 of the Listing Rules. The terms of the 2020 A Shares Participation Scheme (Phase III) are summarized below.

#### *(a) Purpose*

The purposes of the 2020 A Shares Participation Scheme (Phase III) are to align the interests of our Company, our shareholders and key employees, to attract and retain core talent, to enhance the initiative of our employees, and to support our Company’s long-term strategy and sustainable development.

#### *(b) Type and Source of Shares*

The A Share Incentives are granted in the form of participation Shares (“**Participation Shares**”). The Shares underlying the scheme shall be Participation Shares issued by our Company, which were repurchased from the secondary market.

#### *(c) Administration*

The 2020 A Shares Participation Scheme (Phase III) is subject to the approval of the Company’s general meeting and will be administered by a management committee (the “**Management Committee**”) authorized by the participants.

#### *(d) Participants*

Persons eligible to participate in the 2020 A Shares Participation Scheme (Phase III) are the Directors, supervisors, senior management, core technical and business personnel and other core backbone employees of the Company, and other employees as determined by the Board.

#### *(e) Maximum Entitlement of a Participant*

The number of Shares granted to any individual participants under the 2020 A Shares Participation Scheme (Phase III) shall not exceed 1% of our Company’s total [REDACTED]. The total number of Participation Shares involved with 2020 A Shares Participation Scheme (Phase III) shall not exceed 10% of the total outstanding [REDACTED] of the Company.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *(f) Term*

This term of the 2020 A Shares Participation Scheme (Phase III) commences from the date the Company announces the grant of the Participation Shares and will remain effect for an indefinite period until the earliest of (i) a change of control of the Company; (ii) an early termination upon approval from the participants and the Board; or (iii) the reserve of the 2020 A Shares Participation Scheme (Phase III) fails to meet the funding requirements for distribution. If the reserve of the 2020 A Shares Participation Scheme (Phase III) fails to meet the funding requirements for distribution, the 2020 A Shares Participation Scheme (Phase III) shall automatically terminate. The Management Committee shall then proceed to liquidate the assets of the 2020 A Shares Participation Scheme (Phase III). After paying relevant taxes and fees, the remaining assets shall be distributed to the participants in proportion to their respective shareholdings.

### *(g) Lock-up Arrangements*

The lock-up arrangements under the 2020 A Shares Participation Scheme (Phase III) are determined according to the Articles of Association and applicable PRC laws and regulations.

Participation Shares granted under the 2020 A Shares Participation Scheme (Phase III) are generally subject to a lock-up period of 24 months with a statutory lock-up of 12 months from the date of grant. The 2020 A Shares Participation Scheme (Phase III) shall comply with the prohibited period stipulated by the CSRC and the Shenzhen Stock Exchange. During the lock-up period, unless otherwise provided by laws, administrative regulations, or approved by the Management Committee, the Participation Shares held by the participants under the 2020 A Shares Participation Scheme (Phase III) shall not be transferred, pledged, or otherwise disposed of in a similar manner.

### *(h) Distributions*

The 2020 A Shares Participation Scheme (Phase III) provides staged distributions of stock proceeds from sale of Participation Shares:

- (i) In the first year after the expiration of the [REDACTED] period, participants shall receive the first stock proceeds distribution from the Management Committee, corresponding to 20% of the initial scale of the 2020 A Shares Participation Scheme (Phase III);
- (ii) In the second year after the expiration of the [REDACTED] period, the Management Committee shall distribute stock proceeds, corresponding to 20% of the initial scale of the 2020 A Shares Participation Scheme (Phase III) every two years;
- (iii) After the above rounds of distributions, any remaining stock proceeds of the participants under the 2020 A Shares Participation Scheme (Phase III) shall be available for withdrawal in a lump sum upon their retirement.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *2025 A Shares Participation Scheme (Phase IV)*

The following is a summary of the principal terms of the 2025 A Shares Participation Scheme (Phase IV). The terms of the 2025 A Shares Participation Scheme (Phase IV) do not involve any grant of A Shares by our Company after the [REDACTED] and are not subject to the provisions of Chapter 17 of the Listing Rules. The terms of the 2025 A Shares Participation Scheme (Phase IV) are summarized below.

#### *(a) Purpose*

The purposes of the 2025 A Shares Participation Scheme (Phase IV) are to align the interests of our Company, our shareholders and key employees, to attract and retain core talent, to enhance the initiative of our employees, and to support our Company’s long-term strategy and sustainable development.

#### *(b) Type and Source of Shares*

The A Share Incentives are granted in the form of participation Shares (“**Participation Shares**”). The Shares underlying the scheme shall be Participation Shares issued by our Company, which were repurchased from the secondary market or A shares held in the repurchase account of the Company.

#### *(c) Administration*

The 2025 A Shares Participation Scheme (Phase IV) is subject to the approval of the Company’s general meeting and will be administered by a management committee (the “**Management Committee**”) authorized by the participants.

#### *(d) Participants*

Persons eligible to participate in the 2025 A Shares Participation Scheme (Phase IV) are the Directors, supervisors, senior management, core technical personnel and other core backbone employees of the Company, and other employees as determined by the Board.

#### *(e) Maximum Entitlement of a Participant*

The number of Shares granted to any individual participants under the 2025 A Shares Participation Scheme (Phase IV) shall not exceed 1% of our Company’s total share capital. The total number of Participation Shares involved with 2025 A Shares Participation Scheme (Phase IV) shall not exceed 10% of the total outstanding share capital of the Company.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### *(f) Term*

This term of the 2025 A Shares Participation Scheme (Phase IV) commences from the date the Company announces the grant of the Participation Shares and will remain effect for an 60 months until the earliest of (i) a change of control of the Company; (ii) an early termination upon approval from the participants and the Board; or (iii) the reserve of the 2025 A Shares Participation Scheme (Phase IV) fails to meet the funding requirements for distribution; (iv) the Participation Shares were all sold on or before two months of the end of term. If the reserve of the 2025 A Shares Participation Scheme (Phase IV) fails to meet the funding requirements for distribution, the 2025 A Shares Participation Scheme (Phase IV) shall automatically terminate. The Management Committee shall then proceed to liquidate the assets of the 2025 A Shares Participation Scheme (Phase IV). After paying relevant taxes and fees, the remaining assets shall be distributed to the participants in proportion to their respective shareholdings.

### *(g) Lock-up Arrangements*

The lock-up arrangements under the 2025 A Shares Participation Scheme (Phase IV) are determined according to the Articles of Association and applicable PRC laws and regulations.

Participation Shares granted under the 2025 A Shares Participation Scheme (Phase IV) are generally subject to a lock-up period of 36 months from the date of grant. The lock-up period will be released in tranches of 40%, 30% and 30% in release periods that occur (a) the first trading date after 12 months from the date of grant; (b) between the first trading date after 12 months from the date of grant and the last trading day up to 24 months from the date of grant; (c) between the first trading date after 24 months from the date of grant and the last trading day up to 36 months from the date of grant. The 2025 A Shares Participation Scheme (Phase IV) shall comply with the prohibited period stipulated by the CSRC and the Shenzhen Stock Exchange. During the lock-up period, unless otherwise provided by laws, administrative regulations, or approved by the Management Committee, the Participation Shares held by the participants under the 2025 A Shares Participation Scheme (Phase IV) shall not be transferred, pledged, or otherwise disposed of in a similar manner.

### *(h) Distributions*

After the expiration of the [REDACTED] period, the stock proceeds from the sale of Participation Shares shall be distributed to the respective participants in proportion to their respective shareholdings, subject to the satisfaction of the conditions for unlocking the participant's Participation Shares as stipulated in the 2025 A Shares Participation Scheme (Phase IV).

If there are Participation Shares that remained unlocked or undistributed Participation Shares, the Management Committee may sell the Participation Shares at an appropriate time based on market conditions, and the corresponding stock proceeds (including any dividends) shall belong to the Company.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### D. OTHER INFORMATION

#### 1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

#### 2. Litigation

As of the Latest Practicable Date, we were not aware of any litigation or arbitration proceedings of material importance pending or threatened against any member of our Group that could have a material adverse effect on our financial condition or results of operations.

#### 3. Sole Sponsor

The Sole Sponsor has applied to the Stock Exchange for the [REDACTED] of, and permission to deal in, our H Shares to be [REDACTED] pursuant to the [REDACTED]. All necessary arrangements have been made enabling the H Shares to be admitted into [REDACTED].

The Sole Sponsor satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules.

The Sole Sponsor will be paid by our Company a fee of US\$500,000 to act as a sponsor to our Company in connection with the [REDACTED].

#### 4. Compliance Advisor

Our Company has appointed Rainbow Capital (HK) Limited as our compliance advisor in compliance with Rule 3A.19 of the Listing Rules.

#### 5. Preliminary Expenses

As of the Latest Practicable Date, our Company has not incurred material preliminary expenses.

#### 6. Promoters

The promoters of our Company are Zhejiang Kangxin Chemical Co., Ltd. (浙江康新化工有限公司), Xinchang County Jingxin Investment Co., Ltd. (新昌縣京新投資有限公司), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (中國科學院上海有機化學研究所), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (中國科學院上海有機化學研究所), Mr. LYU Gang (呂綱), Ms. LYU Yueying (呂岳英), Mr. WANG Guangqiang (王光強), Ms. ZHANG Lihua (張麗娃), Mr. WU Zhengjie (吳政杰), Ms. YANG Yufei (楊鈺菲), Mr. LIN Jun (林軍), Mr. WANG Nengneng (王能能), Mr. TIAN Gengyuan (田庚元). Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or other benefit have been paid, allotted or given or have been proposed to be paid, allotted or given to the above promoters in connection with the [REDACTED] or related transactions in this document.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 7. Consents of Experts

Each of the experts as referred to in “ — 11. Qualification of Experts” in this Appendix has given and has not withdrawn its consent to the issue of this document with the inclusion of its view, report and/or letter and/or legal opinion (as the case may be) and references to its name included herein in the form and context in which it respectively appears.

Save as disclosed in the section headed [REDACTED] in this document, none of the experts named above has any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in our Company or any of our subsidiaries.

### 8. Binding Effect

This document shall have the effect, if an [REDACTED] is made in pursuance hereof, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

### 9. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance on the exemption provided in section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

### 10. Taxation of Holders of H Shares

Hong Kong stamp duty, currently charged at the ad valorem rate of 0.10% on the higher of the consideration for or the market value of the H Shares, will be payable by the purchaser on every purchase and by the seller on every sale of any Hong Kong securities, including H Shares (in other words, a total of 0.20% is currently payable on a typical sale and purchase transaction involving H Shares). In addition, a fixed stamp duty of HK\$5.00 is currently payable on any instrument of transfer of H Shares. Where one of the parties is a resident outside Hong Kong and does not pay the ad valorem duty due by it, the duty not paid will be assessed on the instrument of transfer (if any) and will be payable by the transferee. If no stamp duty is paid on or before the due date, a penalty of up to 10 times the duty payable may be imposed.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 11. Qualification of Experts

The following are the qualifications of the experts who have given opinion or advice which are contained in this document:

<u>Name</u>	<u>Qualifications</u>
CITIC Securities (Hong Kong) Limited	A licensed corporation to conduct Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activity as defined under the SFO
AllBright Law Offices	Legal advisers as to PRC laws
Frost & Sullivan	Industry consultant
BDO Limited	Certified Public Accountants Registered Public Interest Entity Auditor

### 12. Miscellaneous

- (a) within the two years immediately preceding the date of this document:
  - (i) save as disclosed in the section headed “History, Development and Corporate Structure” in this [REDACTED], no share or loan capital of our Company or any of our subsidiaries had been issued or agreed to be issued or proposed to be fully or partly paid either for cash or a consideration other than cash;
  - (ii) save as disclosed in the section headed [REDACTED] in this document, no commissions, discounts, brokerages or other special terms had been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries;
  - (iii) save as disclosed in the section headed [REDACTED] in this document, no commission had been paid or payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any share in our Company or any of our subsidiaries;
- (b) save as disclosed in the section headed “History, Development and Corporate Structure” in this [REDACTED], no share or loan capital of our Company or any of our subsidiaries had been under option or agreed conditionally or unconditionally to be put under option;
- (c) there are no founder, management or deferred shares, convertible debt securities nor any debentures in our Company or any of our subsidiaries;

**APPENDIX VI**

**STATUTORY AND GENERAL INFORMATION**

- (d) save as disclosed in the section headed [REDACTED] in this document, none of the persons named in the sub-paragraph headed "D. Other Information — 11. Qualification of Experts" in this Appendix is interested beneficially or otherwise in any shares of any member of our Group or has any right or option (whether legally enforceable or not) to subscribe for or nominate persons to subscribe for any securities in any member of our Group;
- (e) our Directors confirm that there has been no material adverse change in the financial or trading position of our Group since October 31, 2025 (being the date to which the latest audited consolidated financial statements of our Group were made up);
- (f) there has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document; and
- (g) no company within our Group is listed on any stock exchange or traded on any trading system and at present, and our Group is not seeking or proposing to seek any listing of, or permission to deal in, the share or loan capital of our Company on any other stock exchange; and there is no arrangement under which future dividends are waived or agreed to be waived.